Related references
Note: Only part of the references are listed.Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response
Xiawei Wei et al.
CELL RESEARCH (2015)
A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma
Hidetaka Akita et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Madduri Srinivasarao et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
Yunfei Wen et al.
CLINICAL CANCER RESEARCH (2015)
Nanopreparations for organelle-specific delivery in cancer
Swati Biswas et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
M. Koebel et al.
BRITISH JOURNAL OF CANCER (2014)
Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency
Alexander Muik et al.
CANCER RESEARCH (2014)
Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations
Robert J. Snelgrove et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment
Stelios Florinas et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances
Nishant S. Gandhi et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Better Therapeutic Trials in Ovarian Cancer
Michael A. Bookman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Non-viral vectors for gene-based therapy
Hao Yin et al.
NATURE REVIEWS GENETICS (2014)
Dual roles of c-Myc in the regulation of hTERT gene
Yuanjun Zhao et al.
NUCLEIC ACIDS RESEARCH (2014)
Global ovarian cancer health disparities
Ganna Chornokur et al.
GYNECOLOGIC ONCOLOGY (2013)
Gene Delivery with Active Targeting to Ovarian Cancer Cells Mediated by Folate Receptor α
Zhiyao He et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2013)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Systemic tumor-specific gene delivery
Max Kullberg et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts
Zhi-Yao He et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Neuroattenuation of Vesicular Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites
Arun Ammayappan et al.
JOURNAL OF VIROLOGY (2013)
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Dan Stark et al.
LANCET ONCOLOGY (2013)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche
Andrea Flesken-Nikitin et al.
NATURE (2013)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Stig E. Bojesen et al.
NATURE GENETICS (2013)
Latest research and treatment of advanced-stage epithelial ovarian cancer
Robert L. Coleman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Telomerase and the search for the end of cancer
Simone Mocellin et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Biologically-Targeted Detection of Primary and Micro-Metastatic Ovarian Cancer
Tracy W. Liu et al.
THERANOSTICS (2013)
VSV-MP gene therapy strategy inhibits tumor growth in nude mice model of human lung adenocarcinoma
X-M Jing et al.
CANCER GENE THERAPY (2012)
The Changing View of High-Grade Serous Ovarian Cancer
Els M. J. J. Berns et al.
CANCER RESEARCH (2012)
Micelles Based on Methoxy Poly(Ethylene Glycol)-Cholesterol Conjugate for Controlled and Targeted Drug Delivery of a Poorly Water Soluble Drug
Junming Li et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2012)
Microbial Carriage State of Peripheral Blood Dendritic Cells (DCs) in Chronic Periodontitis Influences DC Differentiation, Atherogenic Potential
Julio Carrion et al.
JOURNAL OF IMMUNOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Zhiliang Cheng et al.
SCIENCE (2012)
Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus
Phonphimon Wongthida et al.
HUMAN GENE THERAPY (2011)
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
Gooitzen M. van Dam et al.
NATURE MEDICINE (2011)
Efficient Inhibition of C-26 Colon Carcinoma by VSVMP Gene Delivered by Biodegradable Cationic Nanogel Derived from Polyethyleneimine
MaLing Gou et al.
ACS NANO (2010)
Ovarian Cancer Development and Metastasis
Ernst Langyel
AMERICAN JOURNAL OF PATHOLOGY (2010)
Combination of vesicular stomatitis virus matrix protein gene therapy with low-dose cisplatin improves therapeutic efficacy against murine melonoma
Shan Luo et al.
CANCER SCIENCE (2010)
Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Hee Dong Han et al.
CLINICAL CANCER RESEARCH (2010)
Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge
S. Dadashzadeh et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer
Wei Shi et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
Xiaoming Xie et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice
Q. Zhong et al.
ANNALS OF ONCOLOGY (2008)
Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis
Xiao-Bo Du et al.
APOPTOSIS (2008)
Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5′-triphosphate-binding cassette transporter 1 expression
Ivan Tancevski et al.
ENDOCRINOLOGY (2008)
A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus
Ju-mei Zhao et al.
FASEB JOURNAL (2008)
Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice
Xiaojuan Lin et al.
GYNECOLOGIC ONCOLOGY (2007)
Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma
SM Apte et al.
CLINICAL CANCER RESEARCH (2004)
Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression
HR McMurray et al.
JOURNAL OF VIROLOGY (2003)
Why did p53 gene therapy fail in ovarian cancer?
AG Zeimet et al.
LANCET ONCOLOGY (2003)
Spl cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)
S Kyo et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
